Table 1.

Overview of the currently approved ICIs by the United States Food and Drug Administration

Type of ICI	Drug	Indications
Anti-CTLA-4	Ipilimumab (YERVOY)	Melanoma NSCLC RCC HCC Colorectal cancer Malignant pleural mesothelioma
Anti-PD-1	Pembrolizumab (KEYTRUDA)	Melanoma NSCLC SCLCcHL Urothelial cancer HNSCC RCC HCC cSCC	Primary mediastinal large B-cell lymphoma Gastric cancer Esophageal cancer Cervical cancer Merkel cell carcinoma MSI-H or dMMR (colorectal) cancer Endometrial carcinoma Triple-negative breast cancer
	Nivolumab (OPDIVO)	Melanoma NSCLC SCLC cHL Urothelial cancer HNSCC RCC HCC	Esophageal cancer Gastric cancer Gastroesophageal junction cancer Malignant pleural mesothelioma MSI-H or dMMR colorectal cancer
	Cemiplimab (LIBTAYO)	Cutaneous squamous cell carcinoma Basal cell carcinoma NSCLC
Anti-PD-L1	Avelumab (BAVENCIO)	Merkel cell carcinoma RCC Urothelial cancer
	Atezolizumab (TECENTRIQ)	Melanoma NSCLC SCLC Urothelial cancer HCC Triple-negative breast cancer
	Durvalumab (IMFINZI)	NSCLC SCLC

cHL, classical Hodgkin's lymphoma; cSCC, cutaneous squamous cell carcinoma; CTLA-4, cytotoxic T-lymphocyte-associated antigen-4; dMMR, deficient mismatch repair; HCC, hepatocellular carcinoma; HNSCC, head and neck squamous cell carcinoma; ICI, immune checkpoint inhibitor; irAE, immune-related adverse event; MSI-H, microsatellite instability-high; NSCLC, non-small-cell lung cancer; PD-1, programmed cell death protein-1; PD-L1, programmed cell death ligand-1; RCC, renal cell carcinoma; SCLC, small-cell lung cancer.